20 articles
New research reveals how eliminating urokinase plasminogen activator can temporarily protect against diet-induced weight gain and metabolic dysfunction.
A new analysis shows olezarsen reduces apoC-III by up to 75% across chylomicrons, HDL, LDL/VLDL, and Lp(a) in familial chylomicronemia syndrome.
New review examines how elevated uric acid contributes to cardiovascular disease through inflammation and oxidative stress mechanisms.
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
Laroprovstat, a once-daily pill, slashed LDL by 80% when combined with rosuvastatin — rivaling injectable PCSK9 inhibitors.
SHR-1918 antibody dramatically reduced LDL cholesterol in patients with severe genetic hypercholesterolemia through novel pathway.
Large UK study reveals elevated Lp(a) levels raise venous thromboembolism risk by 32% in premenopausal women but not in men or postmenopausal women.
Isolinderalactone from Lindera aggregata root reduces atherosclerotic plaques by targeting key inflammatory pathways in immune cells.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
Meta-analysis of 19,822 people reveals elevated Lp(a) accelerates coronary plaque progression and creates rupture-prone plaques.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
Elevated oxidized phospholipids independently predict major cardiac events after ACS, and alirocumab abolishes that risk signal.
New analysis shows ANGPTL3 inhibitors reduce cholesterol 50% vs 18% for PCSK9 drugs in patients with severe genetic hypercholesterolemia.
New imaging reveals calcified plaques contain active lipid deposits that persist even with very low LDL cholesterol levels below 55 mg/dL.
New oral drug MK-0616 matches injectable PCSK9 inhibitors for lowering LDL cholesterol while offering patient-friendly pill form.
Enlicitide, a daily pill, dramatically reduced LDL cholesterol in patients with familial hypercholesterolemia beyond what statins alone achieved.
A pathological study ties common Lp(a) risk gene variants to specific coronary thrombosis morphologies in sudden cardiac death victims.
